|
|
|
|
|||||
|
|
|
New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves
With significant upside potential, Spyre Therapeutics Inc. (NASDAQ:SYRE) secures a spot on our list of the 10 Best Debt Free Small Cap Stocks to Buy Now.
On September 15, 2025, Spyre Therapeutics Inc. (NASDAQ:SYRE) announced the enrollment of the first patient in its Phase 2 SKYWAY trial targeting multiple autoimmune diseases. This randomized study will assess the company’s lead antibody program in patients who showed no response to standard treatments.
As this is its second Phase 2 program, Spyre Therapeutics Inc. (NASDAQ:SYRE) expects initial data in 2026, with several proof-of-concept readouts planned over the next two years.
Spyre Therapeutics Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company, develops therapies for inflammatory bowel disease. It is one of the Best Debt Free Stocks.
While we acknowledge the potential of SYRE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Benefit From AI and 12 Best Quantum Computing Stocks to Buy According to Wall Street Analysts.
Disclosure: None.
| Oct-13 | |
| Oct-13 | |
| Oct-05 | |
| Oct-03 | |
| Sep-24 | |
| Sep-15 | |
| Aug-05 | |
| Aug-05 | |
| Aug-01 | |
| Jul-03 | |
| Jun-17 | |
| Jun-16 | |
| Jun-06 | |
| May-30 | |
| May-28 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite